Endurant Capital Management LP increased its stake in shares of Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN – Get Rating) by 153.7% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,400 shares of the company's stock after buying an additional 9,331 shares during the period. Endurant Capital Management LP's holdings in Biohaven Pharmaceutical were worth $1,826,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in BHVN. US Bancorp DE boosted its position in Biohaven Pharmaceutical by 19.1% during the first quarter. US Bancorp DE now owns 586 shares of the company's stock worth $70,000 after purchasing an additional 94 shares during the period. Victory Capital Management Inc. boosted its position in Biohaven Pharmaceutical by 6.4% during the first quarter. Victory Capital Management Inc. now owns 2,564 shares of the company's stock worth $229,000 after purchasing an additional 155 shares during the period. Washington Trust Advisors Inc. boosted its position in Biohaven Pharmaceutical by 24.6% during the first quarter. Washington Trust Advisors Inc. now owns 810 shares of the company's stock worth $96,000 after purchasing an additional 160 shares during the period. Raymond James Financial Services Advisors Inc. boosted its position in Biohaven Pharmaceutical by 9.0% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 2,271 shares of the company's stock worth $313,000 after purchasing an additional 188 shares during the period. Finally, Canton Hathaway LLC boosted its position in Biohaven Pharmaceutical by 3.5% during the first quarter. Canton Hathaway LLC now owns 5,860 shares of the company's stock worth $695,000 after purchasing an additional 200 shares during the period. Hedge funds and other institutional investors own 78.19% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on BHVN. Wedbush lowered shares of Biohaven Pharmaceutical from an "outperform" rating to a "neutral" rating and set a $148.50 target price for the company. in a research report on Monday, August 8th. Piper Sandler lowered shares of Biohaven Pharmaceutical from an "overweight" rating to a "neutral" rating and set a $149.00 price objective for the company. in a research report on Thursday, August 18th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $157.17.

Insider Buying and Selling at Biohaven Pharmaceutical

Biohaven Pharmaceutical Trading Up 0.2 %

BHVN stock opened at $150.99 on Tuesday. The firm has a 50 day moving average of $147.39 and a 200-day moving average of $133.36. Biohaven Pharmaceutical Holding Company Ltd. has a 12 month low of $79.01 and a 12 month high of $151.51. The firm has a market capitalization of $10.80 billion, a P/E ratio of -10.19 and a beta of 1.04.

Biohaven Pharmaceutical (NYSE:BHVN – Get Rating) last announced its earnings results on Friday, August 5th. The company reported ($6.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.79) by ($3.42). The business had revenue of $215.08 million for the quarter, compared to analyst estimates of $209.33 million. Sell-side analysts predict that Biohaven Pharmaceutical Holding Company Ltd. will post -13.48 EPS for the current year.

About Biohaven Pharmaceutical

(Get Rating)

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.

Read More

• Get a free copy of the StockNews.com research report on Biohaven Pharmaceutical (BHVN)
• Do These Dividend Achievers Deserve A Place In Your Portfolio?
• Darden Restaurants Takes the Low Road Against Inflation
• Why These 3 Stocks Are Off to Hot September Starts
• Inflation Doesn't Differentiate, But it's Impact Does
• 3 Downgraded Must-Have Stocks To Put On Your Watchlist

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.